FDA Acceptance…

Home PRESS RELEASE FDA Acceptance of a Phase I/II Clinical Trial Using cretostimogene grenadenorepvec Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== -->...

Series B Investment…

Home PRESS RELEASE Series B Investment for Pivotal and Combo Immunotherapy Trials 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== --> Listen to this article now 0:00 0.5x...

$13.57 Million in a Series…

Home PRESS RELEASE $13.57 Million in a Series A Round of Financing to Accelerate Its Ongoing Phase II/III Clinical Trial for Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...